Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy

Open access
Sethi, Roshan V., Shih, Helen A., Yeap, Beow Y., Mouw, Kent W., Petersen, Robert, Kim, David Y., Munzenrider, John E., Grabowski, Eric, Rodriguez‐Galindo, Carlos, Yock, Torunn I., Tarbell, Nancy J., Marcus, Karen J., Mukai, Shizuo, MacDonald, Shannon M.·2014·Cancer

Abstract

BACKGROUND: The leading cause of death among patients with hereditary retinoblastoma is second malignancy. Despite its high rate of efficacy, radiotherapy (RT) is often avoided due to fear of inducing a secondary tumor. Proton RT allows for significant sparing of nontarget tissue. The current study compared the risk of second malignancy in patients with retinoblastoma who were treated with photon and proton RT. METHODS: A retrospective review was performed of patients with retinoblastoma who were treated with proton RT at the Massachusetts General Hospital or photon RT at Boston Children's Hospital between 1986 and 2011. RESULTS: A total of 86 patients were identified, 55 of whom received proton RT and 31 of whom received photon RT. Patients were followed for a median of 6.9 years (range, 1.0 years‐24.4 years) in the proton cohort and 13.1 years (range, 1.4 years‐23.9 years) in the photon cohort. The 10‐year cumulative incidence of RT‐induced or in‐field second malignancies was significantly different between radiation modalities (proton vs photon: 0% vs 14%; P = .015). The 10‐year cumulative incidence of all second malignancies was also different, although with borderline significance (5% vs 14%; P = .120). CONCLUSIONS: Retinoblastoma is highly responsive to radiation. The central objection to the use of RT, the risk of second malignancy, is based on studies of patients treated with antiquated, relatively nonconformal techniques. The current study is, to the authors' knowledge, the first to present a series of patients treated with the most conformal of the currently available external‐beam RT modalities. Although longer follow‐up is necessary, the preliminary data from the current study suggest that proton RT significantly lowers the risk of RT‐induced malignancy. Cancer 2014;120:126–133. © 2013 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28387

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Sethi, R. V., Shih, H. A., Yeap, B. Y., Mouw, K. W., Petersen, R., Kim, D. Y., Munzenrider, J. E., Grabowski, E., Rodriguez‐Galindo, C., Yock, T. I., Tarbell, N. J., Marcus, K. J., Mukai, S., & MacDonald, S. M.
Venue
Cancer
Publisher
Wiley
Published
2013-10-02
Volume
120
Issue
1
Pages
126-133
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1496390158
Cited by
174
References
1
FWCI
13.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. https://app.cochat.ai/papers/10.1002/cncr.28387
The paper
Sethi, R. V., Shih, H. A., Yeap, B. Y., Mouw, K. W., Petersen, R., Kim, D. Y., Munzenrider, J. E., Grabowski, E., Rodriguez‐Galindo, C., Yock, T. I., Tarbell, N. J., Marcus, K. J., Mukai, S., & MacDonald, S. M. (2014). Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. https://doi.org/10.1002/cncr.28387

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.